Allscripts (NASDAQ: MDRX) reported Q3 EPS of $0.16, in-line with the analyst estimate of $0.16. Revenue for the quarter came in at $451 million versus the consensus estimate of $429.71 million.

GUIDANCE:

Allscripts sees FY2017 EPS of $0.61-$0.63, versus the consensus of $0.61.

The company is positively adjusting its 2017 financial outlook, reflecting the company’s year-to-date performance and expectations for the one remaining quarter in 2017.

• The company anticipates non-GAAP revenue to be at the high end of the prior range of between $1.79 billion and $1.82 billion;
• The company anticipates Adjusted EBITDA to be at the high end of the prior range of between $345 million and $365 million; and
• The company affirms its non-GAAP earnings per share growth target of between 10 and 15 percent, or between $0.61 and $0.63 per diluted share.

For earnings history and earnings-related data on Allscripts (MDRX) click here.